Curated News
By: NewsRamp Editorial Staff
September 30, 2026
Quantum BioPharma Advances Lucid-MS to Phase 2 MS Trial, Highlights unbuzzd™
TLDR
- Quantum BioPharma advances Lucid-MS to Phase 2 MS trial and holds a 7 percent royalty on unbuzzd sales, offering a strategic edge.
- Quantum BioPharma's Lucid-MS targets myelin degradation in MS, and its unbuzzd product accelerates alcohol metabolism through a licensed formula.
- Quantum BioPharma's Lucid-MS and unbuzzd aim to improve lives by addressing multiple sclerosis and alcohol misuse for better health.
- Quantum BioPharma's Lucid-MS enters first patient testing for MS while unbuzzd offers a novel way to speed alcohol metabolism.
Impact - Why it Matters
This news matters because it signals tangible progress in the fight against multiple sclerosis, a disease with significant unmet medical need. If Lucid-MS succeeds in clinical trials, it could become a first-in-class treatment that not only slows but potentially reverses myelin damage, offering hope to millions of MS patients worldwide. For investors, Quantum BioPharma’s dual focus on high-impact biotech and a commercial-stage consumer health product like unbuzzd™ provides a diversified risk profile and multiple shots on goal. The royalty stream from unbuzzd™ could generate substantial non-dilutive funding to support the company’s pipeline, while the retained rights for pharmaceutical formulations of alcohol metabolism products open additional long-term opportunities. As the biotech sector continues to innovate, Quantum BioPharma’s advancements underscore the potential of targeted therapies and strategic partnerships in delivering value to patients and shareholders alike.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for multiple sclerosis. Co-Founder and Executive Co-Chair Anthony Durkacz shared this update on The BioMedWire Podcast, noting that Lucid-MS is designed to target myelin and that the upcoming trial will be the first time the drug is tested in MS patients. Preclinical studies have shown the compound can prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The trial represents a significant milestone for the company and for patients living with this challenging neurodegenerative disease.
In addition to Lucid-MS, Quantum BioPharma is making strides with unbuzzd™, an over-the-counter product designed to accelerate alcohol metabolism. Durkacz highlighted clinical results for unbuzzd™ and discussed the commercial opportunity surrounding it. Quantum spun out the OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The latest news and updates relating to QNTM are available in the company’s newsroom.
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances Lucid-MS to Phase 2 MS Trial, Highlights unbuzzd™
